GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.
Hi Dinoman
Honest answer is, i'm not sure, having never had to do it, and it may be worth checking with your broker as they have different stances on Bed & ISA
You can't sell as BOU as they won't exist from 6pm tonight. But yes, i think the only way to get them back into an ISA is to sell and buy back. Some providers do this in a matter of minutes, and you may only lose a few shares. Other take 3 days or more.
Neil
McFish2020
Look at Bould Opportunities website, under "investors" section, then publications/circulars
We will relist as CIZ
Neil
nightye1
i believe the 80% discount is the way that a company is valued. As Allan says, the external companies used a number of models to determine the value. One of the usual models is "discounted cash flow". This is where a value is determined by projection of future cash revenue, but then discounted as it is based on future value, not today's actual value. (as we haven't achieved those revenues yet) In our case, we are also seen as an early stage company, so the discount levied has been determined as 80%. You could look at it another way and see it as a big potential uplift in the share price.
Couple of further things i have gleaned from the information out there.....
The BOD are already in discussions with manufacturers for the reagents.
There is keen interest from institutional investors, which supports the thought that i made previously as to us coming off AIM and listing on main market. Watch this space in the future.
Allan has been talking to high level the Chinese Minister for Health.
We don't have to wait for CE mark /FDA approval to license the technology to other companies., and i expect to see licensing deals being confirmed very shortly with licensing partners, manufacturers and development partners.
I would also take a bet that we will shortly find that we have re-entered into an agreement with a certain Chinese CRO.
SO, friday's share price will be interesting, but the long term is going to be something else!
I said before time is the key factor here, and, IN MY OPINION ONLY, so do your own research,
For those that invested in a certain company i mentioned a few months back, CONGRATULATIONS. If you haven't already seen it, read the RNS issued tonight after trading hours. It just shows that when it all looks lost, dreams can come true.
Neil
Well i guess this is Allan Syms reason for talking to China.
Extracts taken from Hindawi BioMed Research International
[1]. Lung cancer is not only the most common cancer in the world, but also the primary reason for death due to cancer [1]. At present, the number of Chinese patients who were newly diagnosed with lung cancer is about 500 thousand each year, and the number is expected to reach one million by 2025
[3]. Currently, the most often used treatments for NSCLC are surgery, radiotherapy, and chemotherapy, in which the complete surgical resection is the most effective method [4]. Despite the improvements of surgical techniques and instruments in recent years, the overall 5-year survival rate for NSCLC patients after surgery is from 15% to 45% [6]. On the other hand, most patients that were diagnosed with NSCLC were already in the unresectable stage of IIIB or IV and the option of surgery treatment was not feasible, which is the main reason why the overall 5-year survival rate of NSCLC patients is only 12%. However, the overall 5-year survival rate can be increased to 50% if patients can be diagnosed in an early stage
[6]. Currently, the diagnosis of NSCLC mainly depends on X-ray, CT, sputum cytology, fiber bronchoscopy, and cellular pathology. However, X-ray is not sensitive to small lesions and covert lesions; sputum cytology only works on lung cancer originated in the center of airways and has a low detection rate; fiber bronchoscopy is not suitable for early diagnosis due to its invasiveness; cellular pathology cannot precisely determine malignance stages [7]. As such, identifying molecular biomarkers for early diagnosis of NSCLC is urgently needed.
Literature review of the top predicted gene biomarkers suggested that most of them were already considered critical for development of NSCLC.
CIZZLE has the technology to help lung cancer sufferers by increasing the 5 year survival rate by 400% !!!
Neil
Certainly no expert, but hope this helps.
Assuming the resolutions all get passed, (no reason to assume otherwise) you will automatically have the new shares in CIZ ( consolidated 500:1 as per the prospectus.
BOU will not exist after the vote.
Neil
Thanks TRA1,
There are a surprising number of papers by Dr Coverley and co authors on this research, in addition to other authors. So i will never even hope to find/read them all. This quote stood out in one of them though.......
"Conclusions. Unexpected and unusual molecular structure of CIZ1b in native plasma has complicated immunoassay design, and delayed translation of this promising biomarker. However, CIZ1b can now be measured using a high-throughput, hospital-friendly sandwich ELISA format, overcoming an important barrier to further clinical development and application of this blood test for early stage lung cancer."
Dr Coverley is clearly a very intelligent person, and this is her life's work.
Your previous comments re shareholding also caught my attention.
You are quite correct in that the big holders are funds etc. In my business, i have had dealings with Finance Yorkshire (now known as Mercia) on a number of occasions, and it is quite telling that they elected to take an equity stake in CIZ, and a fair sized one at that, rather than a purely capital/interest repayment schedule.
Their eligibility criteria requirement for this type of investment means they are expecting a significant return.
Speaking on a purely personal level, I,m not really so interested in what the share price will be on Friday, as it will be influenced by
1.The new listing
2. Day traders buying in and selling immediately
3. Existing holders that just want their money back after such a long time in suspension etc.
I am far more interested in where this is going over a longer term.
Neil
So, i get in tonight and was 5 or so minutes late in joining the webinar, I was sitting here, laptop on my knee, when halfway through, the damn thing overheated (blocked the fan vent with my knee!) and shut down. By the time i registered again to join, i had missed certain parts.
From what i can see on the comments, i think there is a misconception that we are 2 years away from anything. This is not true. What Allan said is that we are fully funded for the program for the next two years - quite a different thing.
As for "not having a product yet", again i think that is incorrect. We already have a test, but we are looking for CE / FDA marking TO COMMERCIALISE it. Also, he did stress the different revenue streams. One being the licensing of our technology. Something that can be done now. In fact i think that this route is already in progress.
Someone mentioned Grail. This is spin out company (sound familiar?) from Illumina.This was one of the companies i was researching last year, as they were due to IPO on the market around the time we were speculating about the possible target, and issued a prospectus for $100millioin. As it turned out, the IPO wAs pulled, and Illumina bought their own company back for the sum of $8 BILLION That' a hell of a re-rate. They clearly saw the value . Now, just think, what if sometime in the future they bought us too, given that we are in the same market.
I said we were going into an exciting target, and i am more than happy with what i see. .
This has the potential to be MASSIVE.
Neil
"Shortly after the Acquisition, it is proposed that the group, as enlarged by the Acquisition (the “Enlarged Group”) will enter into agreements with selected manufacturers and contract research organisations to conduct the reagent generation, test manufacture and the clinical validation required to achieve CE marking and/or FDA510(K) clearance"
Sounds to me like they are pretty well advanced if they are looking at that.
Been reading up on some of the medical journals ( i really should get out more!) and it looks to me that this is bigger than first seems. We appear to be focusing on lung cancer, but as i said earlier, it also acts as a detector for breast, colon, prostate, gall cancers etc. reading some of the papers submitted, it appears that the CIZ1 protein has 22 variants (that is known at present) and has also been associated with gastric cancers, Alzheimers, rheumatoid athritis, and Ewings tumour.
One that stood out was the incidence of brain tumours. Apparently these are only detectable when they have become solid tumour, and there is no cure, with a very poor prognosis. They can't be detected earlier due to "blood brain barrier" If our test can overcome this barrier, and detect the protein before it becomes tumour, just imagine the medical need. The more i read into this research, the better this looks.
Neil
As i understand it, Fujibio were working with a different set of antibodies to Cizzle, which were not compatible with the company's requirements at that time.
Neil
Wideglide, reading the prospectus, there is still some good news here.
There are other companies looking at liquid biopsy diagnostics, but current prototype tests have relied on Western Blot technique.
This technique is expensive, only demonstrates that the test is able to indicate positive result, gives a high percentage of false positive results, and is less reliable when a hospital setting requiring high throughput is required.
The work Cizzle is developing, refines this technique to the stage where it becomes suitable for scaling up to commercial and manufacture. By the sound of things we are ahead of the competition here.
Something to note is the potential for revenue. There are a number of avenues the BOD are exploring. From global licensing of our technology, direct sales, joint ventures, further product line etc.
One thing of note is China. They have the largest increase in lung cancer cases due to the increased level of people taking up smoking (which goes against the rest of the world where most countries are seeing gradual declines) It seems that the BOD are already actively looking at China, and to engage with a Chinese CRO and marketing partner to enter the lung cancer detection market. It just so happens that our Executive Chairman and cancer specialist (Allan Syms) has connections with China having previously held the position of specialist adviser on China to the Department of International Trade.
I am seeing plenty of positives here. Time is the issue.
PS you queried earlier my stage of entry into Bould. Well i was here in the days of Photonstar, and have a fairly significant amount of shares (well into the 10's of millions) so i will be very heavily down at 10p.
Neil
Neil
He hasn't lost penny as far as i can work out.
I said last year that there were reasons he bought photonstar for £1
One being the tax loss that he can use against future profits of his new company. I believe this to be worth over £1million. Also the availability to him of the tax relief in respect of R&D expenditure. I did say that because of a clause in the sale, we were due to a 50% payment from him should he realise that relief. Well he has. To the tune of £107,000.00 to date. So we are due approx £53,500.00 (incidentally this should have been paid to us by April 2020, and which i believe, still has not been paid)
Add to that the fact that he has the option on admission to exercise 7,603,432 shares as the warrants from Peterhouse. At what exercise price? He didn't purchase those at 10p did he? And that is on top of his initial holding.
So you see, as i said back in November i think it was, he couldn't lose.
Neil
Don't think there will be any chance at all of an open offer before listing. It would change the whole prospectus that has already been submitted.
What they should do, once listed, and the dust has settled, is have an open offer with the proviso that a subscription is only open to those who held shares as of 04/10/2019. That would guarantee that only us that have been affected will see a benefit. As a side issue, it would also raise a bit of capital for the company.
Neil
Neil
Rooblertwo
This is the question i submitted:
I, and fellow shareholders welcome the long awaited proposed RTO.
However, we feel that we have not been recognised.
We have supported the proposals and funding of Bould Opportunities prior to suspension, and subsequent de-listing, and have had our money tied up for 19 months. We now find that upon re- listing, the value of our investment has been significantly (for most) reduced. This was to be expected to a point in all honesty, but the issue we have is that anyone buying shares on day 1 of listing will be buying at a much lower price than we did, and will probably sell immediately on a rise.
Whilst i recognise the reason for a placing to achieve a fast capital injection, why did the board not give us, the very people that kept this company alive, a chance to participate in an open offer? This would have at least given us the opportunity to reduce our average price, and made it a little fairer.
Best regards
Neil
Voted in favour, and submitted my question for the webinar
Neil
Tra1 Question 6There are a number of long term shareholders that held shares prior to suspension, and have had their funds tied up without recourse for a substantial time frame. I understand the reason for the placing to get quick capital injection, but why were these shareholders not given the opportunity of an open offer. The general feeling of these shareholders is that we have been put at a significant disadvantage, in that anyone buying shares on relisting will be buying them cheaper than us, the shareholders that supported this company through suspension, de-list and RTO. An open offer would have at least allowed us to reduce our average and make for a fairer result.HrlfcYou may not be convinced yet, but someone was. The placing was made without being underwritten. What this means is that they didn't need the protection of underwriting, as they already have an investor(s) (institution probably at that level) that has made an irrevocable agreement to take the entire issue. Not only that, but they took them at 10p per share. Generally speaking , they command a discount for this. Trust me, they aren't investing £2.2million to see a return of 10 or 20 % This is one of the reasons that we are listing on the main market, and not AIM, as this gives us exposure to the big institutional investors, as i said last year. We are wanting to attract the big boys now. Neil
"Can anyone imagine just how big the market would be for both Prostrate and Breast cancer detection alone!"
Consider this.....
Consultant led referrals for treatment (not ALL cancer i hasten to add) -
Patients waiting over 18 weeks is currently 1,750,000
Patients waiting over 52 weeks is currently 390,000
Total patients on waiting list is currently 4,600,000
Patients on waiting list over 52 weeks is now at a 240 fold increase on 12 months ago mainly as a result of reduced operations because of the pandemic, and is now at a 14 year high.
Chest CT scan costs £400
Breast CT scan costs £600
our test using Cizzle costs approx. £200
The saving to the NHS amounts to approx £62.3 million over 2 years!
And frees up CT scanners for other needs.
Does it get any better?
Neil
At the risk of upsetting some people (which is not the intention i assure you) There is no chance of starting again and getting a better deal. The costs of an abortive result of a no vote, would leave us with little if any money to start again. Even if we could, do you really want to start this process all over again? I cannot understand the statements that the BOD have shafted us. On what basis is that assumption? That they haven't found us a company that will give us £1 a share on day one? 18 months or so ago, we were all but bust. They were tasked with getting us into a company that has prospects of giving shareholders the best return they could. I believe they have. OK it may take time, but what was the alternative? A lot of you had resigned yourselves to the fact that we were not going to come back to market, and you accepted that you lost all your money. Well we are coming back, and you haven't lost your money. You may make a loss, you may make a fortune. That is what this trading shares is all about. I see comments that state " i have lost so much" i will be so down" etc. How do you know? We haven't resumed trading yet. You can't possibly know if the opening price will be up down or what., so those comments are not yet valid. i,m not saying i am happy with the long wait, but i am happy that we haven't gone T**TS up and there is now possibility of a return.The market we are entering is a huge one and if we get it right and prove commerciality of the products, who is to say that the big players in this sector don't come long and take us over? They want small companies like us to develop the process, and then when they see it is a success, they want it.A question was asked as to can liquid biopsy be used in other cancer detection. The answer is yes. Colon, Breast, Prostate, Gall etc.Neil
3 weeks before we are back trading
Neil
PLEASE DO NOT speculate on the target. We are only 3 weeks away from our prayers being answered! To do so at this late stage could be a real threat to the outcome.
Some of you may have worked out who it is, but can i just say keep it to yourselves just a little while longer.
We are about to enter into a segment that according to analysts is worth approx £6billion over the next 3 years. Apologies to PersonA , for not answering you yesterday, but i said last week that i had requested an update, and a response. Yesterday afternoon i made a follow up telephone call, and was awaiting the response. The update we received was better than i thought, having actually given us a date for listing. Well done to all for sticking with it. (not that we had much of a choice!)
We are about to enter a very exciting period. On listing, i believe that it will be very volatile until the dust settles.
No doubt some members here are so relieved when we list, that they will be happy to sell and get their money back. That is a fair position, having waited so long and the frustration felt, and your decision is yours alone to make. Others may see the benefit of holding out for the big reward. My own position will be to hold, as we are in this at such an early stage. Whatever your position is, i wish you all the best.
Neil
Still think i am full of sh*t?
Neil